U.S. District Judge Dabney Friedrich last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies.

Breaking News

Breaking: Another Federal Judge Issues a Mixed Opinion in 340B Contract Pharmacy Litigation, this Time in Novartis and United Therapeutics’ Cases

A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too was mixed, but it leaned more toward the drug industry’s position than the preceding decision.

U.S. District Judge Dabney Friedrich of the District of Columbia, in a Nov. 5 joint ruling in Novartis and United Therapeutics’ lawsuits against the federal government, held that any future federal enforcement action against the companies’ 340B contract pharmacy policies “must rest on a new statutory provision, a new legislative rule, or a well-developed legal theory that Section 340B precludes the specific conditions at issue here.”

A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too was mixed, but it leaned more toward the drug industry’s position than the preceding decision.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer